课题基金 / 基金详情

Investigation of the cell-intrinsic immune response and the antiviral efficacy of interferons against SARS-CoV2

Investigation of the cell-intrinsic immune response and the antiviral efficacy of interferons against SARS-CoV2
细胞内在免疫反应和干扰素对 SARS-CoV2 的抗病毒功效的研究
批准号:
458633830
负责人:
Dr. Marco Binder
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2021
资助国家:
德国
项目状态:
已结题
起止时间:
2020-12-31 至 2021-12-31

项目摘要

项目成果

Dr. Marco Binder的其他基金

相似基金

相关文献

中文摘要
翻译
新型冠状病毒SARS-CoV2是一种正链RNA病毒。RNA病毒感染通常涉及细胞固有免疫系统的分子感受器,即所谓的模式识别受体(PRRs),最重要的是RIG-I样受体(RLR)家族。RLRs触发一系列信号级联反应,最终导致炎症细胞因子(通过转录因子NFκB)和抗病毒细胞因子的转录、产生和分泌,最突出的是I型和III型干扰素(IFN)(通过IRF3)。此外,对这些抗病毒途径的强烈刺激也会导致细胞死亡,潜在地产生危险信号(抑制),进一步刺激组织中的炎症过程。在SARS-CoV2感染的具体案例中,我们和其他人已经证明,该病毒(和近亲)强烈抑制IRF3的激活,从而抑制IFN的产生。相反,它不会阻止核因子κB的激活和炎性转录程序的诱导。这种对细胞固有防御途径抗病毒分支的选择性阻断会导致免疫反应的强烈扭曲,很可能导致观察到的炎症性“细胞因子风暴”的诱导,再加上病毒诱导的细胞病变对组织的直接破坏,很可能形成免疫过度激活的基础,最终导致新冠肺炎的过度炎症和免疫病理特征。如果是这样的话,与其说是先天性免疫反应在新冠肺炎的发展中起到了不利作用,不如说是未能遏制病毒的复制和传播。因此,一种有前景的治疗方案可能是从药物上抑制PRR信号,防止炎性细胞因子的产生,并可能抑制上皮细胞死亡的诱导。将这种抑制与外源性IFN的应用相结合,可以提供一种高效的双管齐下的治疗方案,同时影响病毒复制和炎症基础COVID-19。在拟议的项目中,我们将表征参与诱导细胞程序性死亡和激活炎症转录程序的信号通路。我们将进一步研究不同类型的干扰素对SARS-CoV2的抗病毒效果,包括未被研究的I型干扰素kappa。这一为期一年的研究计划的集体结果将告诉我们所建议的治疗方法的可行性,并为长期深入研究SARS-CoV2的抗病毒免疫奠定基础。
英文摘要
The novel coronavirus, SARS-CoV2, is a plus-strand RNA virus. RNA virus infection very generally engages molecular sensors of the cell-intrinsic innate immune system, so called pattern recognition receptors (PRRs), most importantly of the RIG-I-like receptor (RLR) family. RLRs trigger a signaling cascade culminating in the transcription, production and secretion of inflammatory cytokines (via the transcription factor NFκB) and antiviral cytokines, most prominently type I and III interferons (IFNs) (via IRF3). Additionally, strong stimulation of those antiviral pathways also leads to the induction of cell death, potentially generating danger signals (DAMPs) that further stimulate inflammatory processes in the tissue. In the specific case of SARS-CoV2 infection, we and others have shown that the virus (and close relatives) strongly inhibits the activation of IRF3 and, hence, the production of IFNs. In contrast, it does not block activation of NFκB and the induction of an inflammatory transcriptional program. This selective blockage of the antiviral branch of cell-intrinsic defense pathways leads to a strongly skewed immune response, likely contributing to the observed induction of an inflammatory “cytokine storm”, which together with direct tissue destruction by virus-induced cytopathy most likely forms the basis of immune hyperactivation, eventually leading to the excessive inflammation and immunopathology characterizing COVID-19. If this is the case, innate immune responses rather play a detrimental role in the development of COVID-19, but fail to contain viral replication and spread. A prospective therapeutic regimen may therefore be the pharmacological inhibition of PRR signaling, preventing the production of inflammatory cytokines and possibly dampening the induction of epithelial cell death. Combining such inhibition with the administration of exogenous IFNs could provide a highly efficacious two-pronged therapeutic option, impacting both, viral replication and the inflammatory basis COVID-19.In the proposed project, we are going to characterize the signaling pathways involved in the induction of programmed cell death and the activation of inflammatory transcriptional programs. We will further investigate the antiviral efficacy of different IFN types against SARS-CoV2, including the understudied type I IFN kappa. The collective results from this one-year research program will then inform us about the feasibility of the proposed therapeutic approach and form the basis for longer-term in-depth studies on antiviral immunity in SARS-CoV2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification and characterization of signal-transducing and regulatory kinases involved in the RIG-I/IRF3-mediated induction phase of the innate antiviral immune-response
国内基金
海外基金
全细胞疫苗Cell@MnO2的乳腺癌术后免疫响应监测与放射免疫治疗研究
  • 批准号:
    QN25H220002
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    顾媛
  • 依托单位:
T-cell Receptor信号通路调控基因的表达机制分子解析
  • 批准号:
    32570839
  • 项目类别:
    面上项目
  • 资助金额:
    50.00万元
  • 批准年份:
    2025
  • 负责人:
    范高峰
  • 依托单位:
染色体外环状DNA以cell-in-cell途径促进基因横向传递和扩增的研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    15.0万元
  • 批准年份:
    2024
  • 负责人:
    王锐智
  • 依托单位:
GMFG/F-actin/cell adhesion 轴驱动 EHT 在造 血干细胞生成中的作用及机制研究
  • 批准号:
    TGY24H080011
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    李鸿鹄
  • 依托单位: